Upstream Bio’s Verekitug Achieves Robust Efficacy in Severe Asthma—Phase 2 VALIANT Trial Signals Major Step Forward
VALIANT Trial Results: Verekitug Delivers Remarkable Reductions in Asthma Attacks
Upstream Bio’s latest top-line results from the Phase 2 VALIANT trial reveal that verekitug, the only clinical-stage antagonist of the thymic stromal lymphopoietin (TSLP) receptor, met its primary endpoint by substantially lowering annualized asthma exacerbation rate (AAER) in adults with severe asthma. Patients receiving 100 mg every 12 weeks saw an AAER reduction of 56% (p<0.0003), while the 400 mg group dosed every 24 weeks achieved a 39% reduction (p<0.02), both compared to placebo. Even the lower 100 mg every-24-weeks regimen produced a significant effect on AAER, although without as strong backing across all secondary measures.
| Dose | AAER Reduction vs. Placebo | Lung Function (FEV1, mL, Week 60 vs. Placebo) | FeNO Suppression vs. Placebo at Week 60 (ppb) | Reduction in FeNO from Baseline (%) |
|---|---|---|---|---|
| 100 mg q12w | 56% (p<0.0003) | 122 | 20.4 (p<0.0003) | 43.5% (p=0.03) |
| 400 mg q24w | 39% (p<0.02) | 139 | 26.3 (p<0.0001) | 44.9% (p=0.03) |
Sustained Improvements in Lung Function and Inflammation
Beyond reducing exacerbations, verekitug produced meaningful improvements in lung function and airway inflammation. Forced expiratory volume in one second (FEV1) improved by 122 mL in the 100 mg group and 139 mL in the 400 mg group at week 60 versus placebo. These are clinically relevant gains for patients struggling to breathe. Exhaled nitric oxide (FeNO), a marker of airway inflammation, fell by 20.4 ppb (100 mg) and 26.3 ppb (400 mg), with both regimens showing over 43% reductions from baseline—a signal of reduced allergic airway activity.
Safety Profile Consistent with Prior Studies
Crucially, both dosing schedules were well tolerated, with verekitug’s safety profile aligning with previous studies. No concerning signals or unexpected adverse events were highlighted, supporting its continued development.
Long-Term Commitment and Phase 3 Plan Highlight Broader Potential
The trial’s patient retention rate also underlines the treatment’s promise: over 90% of eligible participants opted to join the long-term extension (VALOUR) study, signaling both efficacy and tolerability in real-world settings.
With the completion of VALIANT, Upstream Bio will now aim to initiate Phase 3 trials for severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), pending regulatory interactions. Simultaneously, ongoing Phase 2 studies in COPD demonstrate commitment to broader respiratory indications.
What This Means for Patients: A Competitive Efficacy Profile with Less Frequent Dosing
Verekitug’s distinct mechanism targeting the TSLP receptor and its less frequent dosing requirements could set it apart from other biologics for severe asthma, where the need for better disease control and fewer injections remains high. With roughly 1.3 million biologic-eligible severe asthma patients in the US, demand for therapies that are both effective and practical is substantial.
Key Takeaway: Phase 2 Data Strongly Support Next Steps
For clinicians, researchers, and investors, the VALIANT trial’s positive top-line results offer compelling evidence that verekitug could become a significant new therapeutic for severe asthma. As Upstream Bio gears up for Phase 3 and awaits further regulatory feedback, all eyes will be on future data and presentations that could confirm verekitug’s role in advancing care for those living with severe respiratory disorders.
Upstream Bio will discuss these findings further in a webcast today at 8:00 a.m. ET. For more details, visit the company’s Investor Relations website.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI